Gokhan Guner
Managing Partner @ ACT Venture Partners
Gokhan Guner is a seed investor at ACT Venture Partners focused on Health Care and Advanced Materials. Venture Capital investor, Angel Investor, Deep-tech startups, Technology commercialization, AI, Big Data/Analytics, IoT, Med-tech, Mobility, Electronics and Telecom.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Gokhan Guner invests in
Stages Gokhan Guner invests in
Countries Gokhan Guner invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.1M–$1.4M
Investment Focus
Industry
- Health Care 2 (33%)
- Advanced Materials 2 (33%)
- Artificial Intelligence 2 (33%)
- Pet 1 (17%)
- Sensor 1 (17%)
Stage
- Seed 2 (33%)
- Venture - Series Unknown 2 (33%)
- Pre-Seed 1 (17%)
- Funding Round 1 (17%)
Country
- Spain 2 (33%)
- Ireland 2 (33%)
- France 1 (17%)
- Turkey 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Meddenovo is at the forefront of AI-driven drug discovery, pioneering a specialized technology platform designed specifically for cyclic peptides. Our innovative approach leverages a unique blend of AI technologies and molecular modeling to significantly enhance the efficiency and success rates of drug development processes. Cyclic peptidesrepresent a groundbreaking class of compounds in pharmaceutical research. These molecules combine the best attributes of small molecules and large biologics, offering exceptional binding affinities, stability, and specificity. At Meddenovo, we are leaders in harnessing the potential of cyclic peptides, developing tailored solutions that push the boundaries of traditional drug discovery. Beyond small organic molecules, our expertise extends to peptide-based medicines and metal chelators, giving us a competitive edge in novel drug research and development. We excel in creating unique chemical spaces tailored to your needs and provide custom computational solutions for predicting drug resistance, elucidating biochemical reaction mechanisms, and conducting metal affinity analysis. At Meddenovo, we are dedicated to precision and reliability in drug discovery. Our approach reduces failure rates and improves outcomes, accelerating the journey from research to market. Our mission is to empower scientists worldwide with advanced, user-friendly AI tools, democratizing access to cutting-edge drug discovery technologies. | $1.1M / Pre-Seed / Jul 31, 2024 | ||
| Nextmol is a Barcelona-based startup specialized in computational chemistry. It develops a software platform to accelerate the design of new chemicals through molecular modeling and artificial intelligence for a more efficient R&D. Nextmol shortens the path to chemical innovation over the traditional lab approach thanks to its ability toperform unlimited testing via computations. Furthermore, computations provide key insights about the physico-chemical behavior of the candidate molecules. Nextmol is a spin-off company of the Barcelona Supercomputing Center, one of the largest supercomputing facilities in Europe. | Venture - Series Unknown / May 27, 2024 | ||
| Rototip is a manufacturing Marketplace. | $1.1M / Seed / Feb 26, 2024 | ||
| Senoptica has created a novel sensor that helps Global Retailers increase category sales through reducing food waste | $1.4M / Seed / Dec 21, 2020 | ||
| Gudog connects dog owners with the experienced pet sitters, ie. it facilitates the task of finding an ideal pet sitter nearby making it easy as one, two, three. It offers a wide range of services provided in a fun, relaxed manner yet with a complete safety and no risk involved. Dog owner also can choose to be updated in the real time via email,website or smartphone. A clear and easy to use platform offers an effortless online booking and guarantees a secure payment process.Gudog mission is to solve issues dog owners face on a regular basis by offering innovative solutions, combining technology and pet-knowledge. The major dilemma a dog owner encounters is the necessity to ensure a good care for his four legged friend at times when he or she is not able to take care of it himself. Prior to Gudog, the only solution were dog kennels. However, spending time in a dog kennel implies the dog being put under a lot of stress related to the change of habits. Moreover, in a dog kennel the dog spends most of the time in a cage - all of this is not the ideal environment a dog owner could wish for his pet. Gudog was born out of a desire to provide an alternative. | Venture - Series Unknown / Sep 25, 2019 | ||
| AventaMed is an emerging medical device company |
Co-Investors
About ACT Venture Partners
ACT Venture Partners (ACT VP) is a venture capital firm that invests in early-stage deep-tech startups. ACT VP invested in 25 startups in total. ACT's investment philosophy is to identify early-stage ventures and back technical founders with visions and abilities to transform a market or an industry. ACT's target entrepreneurs developbreakthrough products and technologies, establish new market footholds or pursue novel business models.
ACT Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Duy Louis Tran
Investment Analyst
|
|||
Erhan Z. Kilicozlu
Managing Partner
|
|||
|
Gokhan Guner
Managing Partner
|
|||
Gozde Baloglu
Associate
|
|||
Gurcan Ozan
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Gokhan Guner invest in?
Gokhan Guner invests primarily in Health Care, Advanced Materials and Artificial Intelligence startups, most often at Seed and Venture - Series Unknown stage. Most of the 6 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Gokhan Guner's check size?
Gokhan Guner typically joins rounds of $1.1M–$1.4M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Gokhan Guner participates in.
How do I contact Gokhan Guner?
Public channels for Gokhan Guner include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gokhan Guner last invest?
The most recent investment recorded for Gokhan Guner closed in Jul 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
